Valeant' Bausch + Lomb Begins Distribution Of VYZULTA 0.024% To U.S. Wholesalers

(RTTNews) - Valeant Pharmaceuticals International, Inc.'s (VRX, VRX.TO) wholly owned subsidiary, Bausch + Lomb announced that it has begun distributing VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% to U.S. wholesale pharmaceutical distributors. VYZULTA will be available to patients across the United States through their local pharmacies within the next few days.

VYZULTA, the first prostaglandin analog with one of its metabolites being nitric oxide (NO), is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024% is a prostaglandin analog indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.